La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ApicHope Pharmaceutical Résultats passés
Passé contrôle des critères 1/6
ApicHope Pharmaceutical has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.4% per year. ApicHope Pharmaceutical's return on equity is 5.3%, and it has net margins of 7.2%.
Informations clés
8.3%
Taux de croissance des bénéfices
8.2%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 12.4% |
| Rendement des fonds propres | 5.3% |
| Marge nette | 7.2% |
| Prochaine mise à jour des résultats | 29 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?
Jun 27
ApicHope Pharmaceutical (SZSE:300723) Is Paying Out A Larger Dividend Than Last Year
May 27ApicHope Pharmaceutical's (SZSE:300723) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Bearish: Analysts Just Cut Their ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Revenue and EPS estimates
May 02ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet
Mar 15Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings
Feb 27Ventilation des recettes et des dépenses
Comment ApicHope Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 2,410 | 174 | 1,266 | 316 |
| 31 Dec 23 | 2,503 | 185 | 1,425 | 301 |
| 30 Sep 23 | 2,515 | 307 | 1,495 | 249 |
| 30 Jun 23 | 2,641 | 341 | 1,631 | 250 |
| 31 Mar 23 | 2,480 | 322 | 1,571 | 204 |
| 01 Jan 23 | 2,280 | 291 | 1,465 | 190 |
| 30 Sep 22 | 2,161 | 285 | 1,405 | 160 |
| 30 Jun 22 | 2,151 | 344 | 1,410 | 160 |
| 31 Mar 22 | 2,200 | 319 | 1,446 | 150 |
| 31 Dec 21 | 2,199 | 307 | 1,448 | 142 |
| 30 Sep 21 | 2,135 | 317 | 1,388 | 169 |
| 30 Jun 21 | 1,978 | 263 | 1,273 | 149 |
| 31 Mar 21 | 1,851 | 250 | 1,169 | 146 |
| 31 Dec 20 | 1,675 | 226 | 1,037 | 135 |
| 30 Sep 20 | 1,640 | 173 | 1,009 | 111 |
| 30 Jun 20 | 1,515 | 117 | 947 | 96 |
| 31 Mar 20 | 1,641 | 138 | 1,006 | 90 |
| 31 Dec 19 | 1,637 | 144 | 985 | 98 |
| 30 Sep 19 | 1,537 | 243 | 847 | 87 |
| 30 Jun 19 | 1,435 | 234 | 764 | 101 |
| 31 Mar 19 | 1,395 | 219 | 727 | 102 |
| 31 Dec 18 | 1,430 | 208 | 708 | 91 |
| 30 Sep 18 | 1,426 | 180 | 666 | 97 |
| 30 Jun 18 | 1,477 | 167 | 592 | 112 |
| 31 Mar 18 | 1,467 | 166 | 548 | 94 |
| 31 Dec 17 | 1,380 | 157 | 514 | 81 |
| 30 Sep 17 | 1,399 | 156 | 539 | 41 |
| 31 Dec 16 | 1,251 | 137 | 479 | 0 |
| 31 Dec 15 | 1,028 | 60 | 436 | 0 |
| 31 Dec 14 | 793 | 40 | 319 | 0 |
| 31 Dec 13 | 508 | 33 | 134 | 0 |
Des revenus de qualité: 300723 has a large one-off gain of CN¥50.0M impacting its last 12 months of financial results to 31st March, 2024.
Augmentation de la marge bénéficiaire: 300723's current net profit margins (7.2%) are lower than last year (13%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 300723's earnings have grown by 8.3% per year over the past 5 years.
Accélération de la croissance: 300723's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 300723 had negative earnings growth (-46%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 300723's Return on Equity (5.3%) is considered low.